NuProbe is a genomics and molecular diagnostic company enabling diseases to be detected, treated and cured at early stages. NuProbe has proprietary technology to reduce costs and enhance the sensitivity of next-generation sequencing (NGS) and qPCR assays by pioneering ultrasensitive and highly-multiplexed assays. Success already includes the development of ‘Blocker Displacement Amplification’ to amplify low-abundant sequence variants in qPCR and ‘Quantitative Amplicon Sequencing’ to detect mutations and copy number variations. NuProbe continues to develop innovative assays to accelerate cancer research and works at the cutting edge of genomics.